DMX 101 - Dimerix Bioscience
Alternative Names: DMX-101 - Dimerix BioscienceLatest Information Update: 06 Nov 2023
At a glance
- Originator Dimerix Bioscience
- Class Anti-inflammatories; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Irritable bowel syndrome therapies; Opioid analgesics; Recombinant fusion proteins; Tumour necrosis factors
- Mechanism of Action Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Irritable bowel syndrome
- Phase I Pain
Most Recent Events
- 21 Sep 2023 Phase-I clinical trials in Pain (PO), before September 2023
- 21 Sep 2023 Phase-II/III clinical trials in Irritable bowel syndrome (PO), before September 2023
- 21 Sep 2023 DMX 101 receives Fast track status from the US FDA for Irritable bowel syndrome, prior to September 2023 (Dimerix Bioscience pipeline, September 2023)